ClinicalTrials.gov Identifier: NCT02863536
Study type: Interventional prospective trial
Indication studied: Recurrent Bacterial Vaginosis
Design: Interventional, non-controlled, multicenter trial with a prospective design on one cohort of patients
Name and address of Sponsor: EFFIK Italia S.p.A Via dei Lavoratori, 54 Milano (Italy)
Name and address of CRO: Opera Contract Research Organization (Opera CRO)
10 Cozia Street, Building B 300209 Timișoara (Romania)
Principal Investigator of Coordinating Centre: Dr. Filippo Murina Servizio di Patologia Tratto Genitale Inferiore U.O. Ostetricia e Ginecologia Ospedale Vittore Buzzi - Università degli Studi di Milano (Italy)
Statement of Compliance: the trial was in accordance to standard UNI EN ISO 14155:2011, the Guidelines for Good Clinical Practices and complied with the current Italian and Romanian legislation concerning the medical device
Rationale and Research Hypothesis
Bacterial Vaginosis (BV) is a polymicrobial disease occurring when the protective lactobacillus vaginal microbiota is impaired and allows an overgrowth of anaerobes and other pathogens, such as Gardnerella vaginalis and Mycoplasma hominis. Because of the several BV-determining risk factors, the etiology and pathogenesis of this disease are not completely understood, the treatment is not always effective, resulting in high recurrence rates. Recurrent Bacterial Vaginosis (RBV) is generally defined as 2-3 episodes of BV per year. The recurrence rates are up to 35% at 1 month, 50% at 3 months, and 70% at 12 months.
The Research Hypothesis for the present study is that rate of recurrence after 3 months of administration with Polybactum® shall significantly decreas in comparison to the baseline condition of the patients. In addition, we hypothesize that the proportion of normal vaginal microbiota will be significantly higher receiving Polybactum® for 3-cycle month.
The primary objective is to evaluate the efficacy of Polybactum® in reducing the rate of recurrence of BV after a 3-cycle month treatment, compared to what reported by appropriate selected international literature.
The secondary objectives of the trial are:
- to evaluate the rate of return to normality of vaginal microflora, defined as vaginal microflora with numerous pleiomorphic lactobacilli, no other bacteria or clue cells or hyphae after a 3-month therapy;
- to evaluate the safety of Polybactum®.
- Recurrence of BV identified by Amsel criteria (vaginal pH, whiff test, homogenous vaginal discharge and clue cells at optical microscopy by phase-contrast; see Annex 3).
- Treatment effects on Lactobacillus microbiota evaluated by vaginal swab (see Annex 4);
- Signs and symptoms of BV (vaginal discharge, burning, erythema, dyspareunia);
- Global Assessment of Efficacy by patient’s diary.
Secondary safety outcomes:
- ADE/SADE/USADE and AE/SAE;
- Global Assessment of Safety.
- BV diagnosed by Amsel criteria (see Annex 3) in the 6-9 days before study, and cured with metronidazole vaginal formulation (gel for 5 days or ovules for 7 days).
- Diagnosis of RBV (at least 2 episodes of BV in the last 12 months including the BV cured before baseline).
- Non lactating women or lactating non amenorrheic women.
- Read and signed informed consent.
- Candidiasis or mixed vaginitis.
- HIV or other immunodeficiency.
- Known allergy to metronidazole or to Polybactum® ingredients.
- Menstruation or pre-menopause/menopause.
- Patients concomitantly included in different interventional clinical trials.
- Unwillingness to provide the informed consent to the trial.
- Time between the last day of last menses and baseline visit > 16 days or ≤5 days.
Concomitant care and interventions not allowed during the trial
- Use of an etonogestrel/ethinyl estradiol vaginal ring (Nuvaring®) or an intrauterine device.
-Ora l or vaginal probioticstic therapy or other vaginal therapies (like douching, spermicide).
- Oral or vaginal probiotics.
Forty-three (43) evaluable patients (55 enrolled).
In medical literature, the mean recurrence rates without treatment is from 30% to 50% within 3 months. Considering to be realistic to have a 40% as mean recurrence rates without treatment also in the present study, using the current medical literature and in addition the recently collected data on recurrence rates pre-post treatment with Polybactum® (data on file, Effik Italia SpA), and assuming that 40% and 15% of the pairs are positive at the first and the second observation, respectively, the correlation between paired observation is 2% and after applying continuity correction, the study required a sample size of 44 pairs to achieve a power of 80% and a one sided significance of 5% for detecting a difference of -0.25 between marginal proportions. Taking into account of a possible 15% screening failure and 20% drop-out rate, 65 patients had to be screened and 55 enrolled (one group chi square test than a proportion equals user specified value non-inferiority. In this multicenter study, the enrolment was performed in a competitive way in the involved Centers. Therefore, each site should have been recruited and treated from 5 to 15 patients. Patients with a recurrence during the study period were considered as treatment failure and not replaced
Five (5) Centers (2 in Italy and 3 in Romania).
Quantitative variables (i.e. demographic) if normally distributed were described through mean ± Standard Deviation (SD), otherwise median, minimum, maximum and interquartile range were showed. Qualitative variables were evaluated using frequencies and percentages.
In order to evaluate changes over time before and after the treatment, Paired t-test (if applicable) or Wilcoxon signed rank sum test were performed for quantitative variables, while McNemar test were used in order to evaluate changes for binary variables, while symmetry test was performed in order to evaluate changes for qualitative (not binary) variables.
The quality and completeness of the collected data were evaluated preliminarily compared to data analysis. If a subject is missing information for one or more variables, even after the resolution of its query, the missing data were not replaced. If a subject was involved in violation of inclusion/exclusion criteria, the respective data were excluded from the analysis.
Polybactum® (medical device Class IIa).
Three (3) cycles treatment one per month. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.
In the 1st cycle the treatment started immediately after the end of metronidazole treatment (the maximum acceptable interval between the two treatments is 24 hrs; the minimum 12 hrs).
In the two following cycles, the same treatment was repeated immediately after the end of the first and second menstrual bleeding.
a) Screening and Baseline Visit (day 1)
The visit must be performed from 12 to 24 hrs after the end of metronidazole treatment.
- physical examination and medical history;
- Amsel criteria (vaginal pH, whiff test, homogenous vaginal discharge and clue cells at optical microscopy by phase-contrast);
- vaginal swab (lactobacilli determination);
- Nugent Score (not mandatory);
- Polybactum given to the patient (in any case the maximum acceptable interval between metronidazole and Polybactum treatment is 24 hrs).
The initial phone interview must be done in concomitance with the 1st Polybactum® ovule administration in the 2nd cycle (28±1 days after the last day of last menses); to check adherence to the treatment, and BV symptoms; visit and Amsel criteria only in suspect of BV recurrence.
The intermediate phone interview must be done in concomitance with the 1st Polybactum ovule administration in the 3rdcycle (28±1 days after the 1st phone contact); to check adherence to treatment, and BV symptoms; visit and Amsel criteria only in suspect of BV recurrence.
This phone interview must be done the day following the last day of 3rd menses (28±1 days after the 2nd phone contact);
- The patient confirm the end of 3 cycles of Polybactum® ;
- The Investigator indicates the patient to avoid sexual intercourses during the 3 days before the Final Visit;
- No visit is requested at this date.
The visit must be performed 4±1 day after the 3rdphone contact (day 72 to day 84 from Baseline):
- evaluation with Amsel criteria, (see above);
- vaginal swab (see above);
- Global Assessment of Safety performed by Investigator;
- Collection of data reported by patient in the Patient Diary (symptoms, adherence and Global Assessment of Efficacy);
- Polybactum® packages returned to the Investigator
- Nugent Score (not mandatory)
f) Follow-up period (12- 15 months, not mandatory)
- Phone Contact after 3 months
- Follow-up visit after 6 months after the Final Visit was performed at site (or 12-15 months from the start of the study).
The final visit will be performed in the timeframe of 12-15 months after the final visit of the study.